The next-generation weight loss drug developed by Metsera, Inc. in the United States has shown good tolerability in an interim clinical trial, with only a very small number of participants dropping out midway, a result that has increased the attractiveness of the pharmaceutical company.
　　Studies show that the drug's weight loss effect is comparable to that of current market leader Eli Lilly.It is comparable to Zepbound, and only about 3% of participants dropped out of the trial. In contrast, some other weight-loss drugs...The dropout rate in the trial was high, with participants often discontinuing the medication due to side effects.
　　John Buse, a professor at the University of North Carolina at Chapel Hill School of Medicine, said while introducing the trial at the Obesity Society Annual Meeting in Atlanta, "The tolerability (of the drug) is excellent."
　　Metsera first disclosed trial data at the end of September. The results showed that after 28 weeks (once a week), the subjects experienced an average weight loss of 14.1%, with a low incidence of nausea and vomiting, and the effect was roughly equivalent to Eli Lilly 's Zepbound.
　　Metsera also revealed that participants experienced continuous weight loss throughout the trial without any plateaus in their weight loss. The company added that side effects were also mitigated if participants started with a low dose and gradually increased it.
　　The results of this trial are attracting much attention, and Pfizer is currently...With Novo NordiskNovo Nordisk is engaged in a fierce bidding war for Metsera. Last week, Novo Nordisk announced that it had made an offer to acquire Metsera for approximately $6 billion, or $56.50 per share.
　　Reports indicate that Pfizer and Novo Nordisk have both raised their offers for Metera, with Pfizer offering $70 per share and Novo Nordisk offering $86.20 per share.
　　As of press time, Metsera's stock price rose more than 13% to $81.
　　Metsera stated that it plans to initiate late-stage clinical trials of the drug later this year and is considering developing it as a once-monthly injection therapy, which would put it on par with Amgen.The company's MariTide is a competitor.
　　However, Metsera did not elaborate further on the feasibility of making the drug a monthly injectable in its report on Thursday.
　　It is worth mentioning that other drug candidates in Metsera's pipeline also have great potential, one of which is expected to have fewer side effects and could even be used in combination with GLP-1 drugs to further enhance weight loss.

https://finance.eastmoney.com/a/202511073557444877.html